Mani Subramanian
Founder at OrsoBio Inc
Profile
Dr. Subramanian joined Samsara as a Venture Partner in 2020.
He will evaluate investment opportunities and incubate innovative R&D efforts within Samsara, focused on developing transformational therapies for the treatment of patients with liver diseases.
He was previously at Gilead Sciences from 2011-2020, where he was the Senior Vice President and Therapeutic Area Head for Liver Diseases.
He was responsible for the developing and implementing the R&D vision for liver diseases, which lead to the approval of compounds for the treatment of patients with viral hepatitis (Sovaldi?, Harvoni ?, Epclusa ?, Vosevi ?, Vemlidy ?), and a compound portfolio in non-alcoholic steatohepatitis, cholestatic liver disease and alcoholic hepatitis.
From 2002-2010, he was at Human Genome Sciences where he led programs in albumin-fusion proteins and monoclonal antibodies for immunology and infectious disease indications, notably clinical development of Zalbin ? for HCV, and Abthrax ? for anthrax.
He started his biotechnology career at Celera Genomics in 2000 and was a major contributor to the proteome annotation of the human, mouse, and anopheles genome sequencing efforts.
Dr. Subramanian received his medical degree at the Armed Forces Medical College, India, completed his PhD (Immunology & Microbiology) at the University at Michigan, Ann Arbor, followed by residency in Internal Medicine at University Hospitals of Cleveland, Case Western Reserve University, and fellowship in Infectious Diseases, with post-doctoral research at the National Institute of Allergy and Infectious Diseases, NIH.
Mani Subramanian active positions
Companies | Position | Start |
---|---|---|
OrsoBio Inc
OrsoBio Inc Miscellaneous Commercial ServicesCommercial Services Orsobio, Inc. is a clinical-stage biopharmaceutical company that focuses on developing therapies to treat obesity and other severe metabolic disorders, such as type 2 diabetes, NASH, and severe dyslipidemias. The company is based in Palo Alto, CA. The company has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism. Orsobio has a team of physicians and scientists who are dedicated to developing therapies to treat organ failure in patients with severe metabolic disorders. The company was founded by Mani Subramanian, who has been the CEO since incorporation. | Founder | 01/04/2020 |
Former positions of Mani Subramanian
Companies | Position | End |
---|---|---|
GILEAD SCIENCES, INC. | President | 01/03/2020 |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Director/Board Member | 01/12/2010 |
Celera Corp.
Celera Corp. Medical/Nursing ServicesHealth Services Celera Corp. provides medical diagnostics services. It offers disease management solutions through a combination of tests and services based on genetics discovery platforms. Celera was founded in 1998 and is headquartered in Alameda, CA. | Corporate Officer/Principal | 01/07/2002 |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | Private Equity Investor | - |
Training of Mani Subramanian
University of Michigan | Graduate Degree |
Armed Forces Medical College | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
GILEAD SCIENCES, INC. | Health Technology |
Private companies | 4 |
---|---|
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Health Technology |
Celera Corp.
Celera Corp. Medical/Nursing ServicesHealth Services Celera Corp. provides medical diagnostics services. It offers disease management solutions through a combination of tests and services based on genetics discovery platforms. Celera was founded in 1998 and is headquartered in Alameda, CA. | Health Services |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | Finance |
OrsoBio Inc
OrsoBio Inc Miscellaneous Commercial ServicesCommercial Services Orsobio, Inc. is a clinical-stage biopharmaceutical company that focuses on developing therapies to treat obesity and other severe metabolic disorders, such as type 2 diabetes, NASH, and severe dyslipidemias. The company is based in Palo Alto, CA. The company has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism. Orsobio has a team of physicians and scientists who are dedicated to developing therapies to treat organ failure in patients with severe metabolic disorders. The company was founded by Mani Subramanian, who has been the CEO since incorporation. | Commercial Services |
- Stock Market
- Insiders
- Mani Subramanian